A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores.

In 30 seconds

This systematic review evaluates the pharmacokinetics (PK) and pharmacodynamics (PD) of antiangiogenic tyrosine kinase inhibitors (TKIs) with high therapeutic drug monitoring (TDM) scores. It included 56 studies focusing on drugs like sunitinib and cabozantinib. A key finding is that cabozantinib 140 mg showed increased exposure under fed conditions, with AUC 0-∞ rising from 60,700 to 95,200 ng·h/ml.

Key findings

• Sunitinib showed dose-dependent increases in exposure in pediatric patients.
• Cabozantinib 140 mg had AUC 0-∞ increase from 60,700 to 95,200 ng·h/ml under fed conditions.
• Sunitinib exhibited a large apparent volume of distribution (V/F) of 3160 L in pediatric gastrointestinal stromal tumor patients.

Why it matters

Understanding the pharmacokinetics and pharmacodynamics of TKIs is crucial for optimizing dosing regimens, which can enhance treatment efficacy and minimize toxicity in cancer patients.